Wellington Management Group’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Wellington Management Group’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,021,558	Closed	-$12.7M	–	2097
2023 Q1	$12.7M	Buy	3,021,558 +262,655	+10%	+$1.36M	﹤0.01%	1042
2022 Q4	$16.6M	Sell	2,758,903 -60,760	-2%	-$332K	﹤0.01%	962
2022 Q3	$16.4M	Buy	2,819,663 +1,286,193	+84%	+$8.02M	﹤0.01%	969
2022 Q2	$9.15M	Buy	+1,533,470	New	+$7.85M	﹤0.01%	1146

Other funds holding CTIC

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group's CTIC Position: Q2 2023 in Review

Wellington Management Group sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 3,021,558 shares — an estimated $12.7M sold.

Wellington Management Group first reported a position in CTIC in Q2 2022 and held it in 4 quarters. The position peaked at $16.6M in Q4 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

Wellington Management Group reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
Wellington Management Group sold 3,021,558 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $12.7M.
Wellington Management Group first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2022 and held it in 4 quarters.
Wellington Management Group's CTI BioPharma Corp. (DE) Common Stock position peaked at $16.6M in Q4 2022.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on Wellington Management Group's 13F filing for Q2 2023, filed 14 Aug 2023.